靶向CD30放射免疫探针的制备及在淋巴瘤患者显像和治疗机制的研究

靶向CD30的免疫治疗已用于复发性难治性霍奇金淋巴瘤/间变性大细胞淋巴瘤（HL/ALCL）,且有较好的临床治疗效果。但这些靶向药物的适应范围仅限于HL/ALCL的某些阶段,而CD30的表达也见于其他类型的淋巴瘤。课题组前期工作中已制备对淋巴瘤细胞表面CD30分子具有良好亲和活力的抗CD30单抗(IMB30-16)。为提高靶向CD30免疫治疗的疗效、扩大靶向CD30免疫治疗的适应症、研究靶向CD30放射免疫探针的治疗机制，本课题组拟利用锝-99m和铼-188标记IMB30-16，通过分子、细胞、动物不同水平的研究，探讨99mTc-IMB30-16和188Re-IMB30-16的标记方法、理化性质；体外活性；体内生物学性质；最终获得的靶向CD30的放射免疫显像和治疗药物，探讨188Re-IMB30-16在CD30阳性淋巴瘤患者的作用机制。

Targeted CD30 immunotherapy has been used in the recurrent, refractory Hodgkin’s lymphoma and anaplastic large cell lymphoma (HL/ALCL). This therapy has good clinical therapy response. However, the indication of these targeted medicine limited in the certain stage of HL/ALCL. The positive expression of CD30 can also be found in other type lymphoma, except for the HL/ALCL. The research group of the project has produced anti-CD30 monoclonal antibody (IMB30-16), which had good affinity with CD30 molecule of lymphoma cell. In order to enhance the therapy response of immune-targeting CD30 medicine, to enlarge the indication of these medicine, and to investigate the mechanism of IMB30-16 in the treatment of CD 30 positive lymphoma, the present research wanted to label IMB30-16 with 99m-Technetium and 188-Rhenium, to find the labeling method and condition, physiochemical property, in vitro activity, in vivo biological property by molecule, cell and animal different level study. At last, we hope to get targeting CD30 radioimmunity imaging and therapy medicine, and to investigate the action mechanism of 188Re-IMB30-16 in CD30 positive lymphoma.